Evidence map›Paper›PMID 34151834›Full record

ArticleCancer biomarkers : section A of Disease markers2021

O-GlcNAcylation in early stages of chronic lymphocytic leukemia: Protocol development for flow cytometry.

Viktória Temesfői, Kinga Molnár, Péter Kaltenecker, Barbara Réger, Árpád Szomor, Zoltán Horváth-Szalai, Hussain Alizadeh, Béla Kajtár, Tamás Kőszegi, Attila Miseta and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Viktória TemesfőiDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
Kinga MolnárDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
Péter KalteneckerLaboratory of Actin Cytoskeleton Regulation, Institute of Genetics, Biological Research Centre, Eötvös Loránd Research Network (ELKH), Szeged, Hungary.
Barbara RégerDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
Árpád SzomorDivision of Hematology, 1st Department of Internal Medicine, Medical School, University of Pécs, Pécs, Hungary.
Zoltán Horváth-SzalaiDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
Hussain AlizadehDivision of Hematology, 1st Department of Internal Medicine, Medical School, University of Pécs, Pécs, Hungary.
Béla KajtárDepartment of Pathology, Medical School, University of Pécs, Pécs, Hungary.
Tamás KőszegiDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
Attila MisetaDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
Tamás NagyDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
Zsuzsanna FaustDepartment of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.
University of Pecs · HUHungarian Research Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies proved that metabolic changes in malignant disorders have an impact on protein glycosylation, however, only a few attempts have been made so far to use O-GlcNAc analysis as a prognostic tool. Glucose metabolism is reported to be altered in hematological malignancies thus, we hypothesized that monitoring intracellular O-GlcNAc levels in Rai stage 0-I (Binet A) CLL patients could give deeper insights regarding subtle metabolic changes of progression which are not completely detected by the routine follow-up procedures.

objectiveIn this proof of concept study we established a flow cytometric detection method for the assessment of O-GlcNAcylation as a possible prognostic marker in CLL malignancy which was supported by fluorescence microscopy.

methodsHealthy volunteers and CLL patients were recruited for this study. Lymphocytes were isolated, fixed and permeabilised by various methods to find the optimal experimental condition for O-GlcNAc detection by flow cytometry. O-GlcNAc levels were measured and compared to lymphocyte count and various blood parameters including plasma glucose level.

resultsThe protocol we developed includes red blood cell lysis, formalin fixation, 0.1% Tween 20 permeabilisation and employs standardized cell number per sample and unstained controls. We have found significant correlation between O-GlcNAc levels and WBC (R2= 0.8535, p< 0.0029) and lymphocyte count (R2= 0.9225, p< 0.0006) in CLL patients. Interestingly, there was no such correlation in healthy individuals (R2= 0.05664 for O-GlcNAc vs WBC and R2= 0.04379 for O-GlcNAc vs lymphocytes).

conclusionAnalyzing O-GlcNAc changes in malignant disorders, specifically in malignant hematologic diseases such as CLL, could be a useful tool to monitor the progression of the disease.

Indexed as

Case-Control StudiesFemaleFlow CytometryGlycosylationHumansLeukemia, Lymphocytic, Chronic, B-CellMaleNeoplasm StagingPrognosisProof of Concept StudyChronic lymphocytic leukemiaflow cytometryimmunometabolismO-GlcNAcylationRL2

Identifiers

PMID34151834
PMCPMC12500057
OpenAlexW3173690994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.